A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain

Trial Profile

A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs NKTR 181 (Primary)
  • Indications Musculoskeletal pain; Pain
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMMIT-07
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 06 Sep 2017 According to a Nektar Therapeutics media release, data from the study has been presented at the 2017 PAINWeek Conference.
    • 06 Sep 2017 Results presented in a Nektar Therapeutics media release.
    • 30 Aug 2017 According to a Nektar Therapeutics media release, dat will be presented at the upcoming 2017 PAINWeek Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top